Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Aprea Therapeutics ( (APRE) ) has issued an update.
On May 14, 2025, Aprea Therapeutics announced its financial results for the first quarter of 2025 and provided updates on its clinical programs. The company reported promising early results from its ATRN-119 clinical trial, with patients showing tumor shrinkage at doses below the recommended Phase 2 level. Additionally, the ACESOT-1051 trial of APR-1051 is progressing, with plans to report preliminary efficacy data later in 2025. Financially, Aprea reported a net loss of $3.9 million for the quarter, with cash reserves expected to support operations into early Q2 2026.
The most recent analyst rating on (APRE) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Aprea Therapeutics stock, see the APRE Stock Forecast page.
Spark’s Take on APRE Stock
According to Spark, TipRanks’ AI Analyst, APRE is a Underperform.
Aprea Therapeutics receives a low overall score due to significant financial challenges, including consistent losses and lack of revenue generation. The company’s strong balance sheet is a positive but is offset by negative cash flows and a reliance on external financing. Technical indicators suggest a bearish trend, and the valuation is unattractive due to a negative P/E ratio and no dividend yield.
To see Spark’s full report on APRE stock, click here.
More about Aprea Therapeutics
Aprea Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative cancer treatments that exploit specific vulnerabilities in cancer cells while minimizing damage to healthy cells. The company’s primary products include ATRN-119, an ATR inhibitor, and APR-1051, a WEE1 inhibitor, both targeting cancers with specific genetic mutations.
Average Trading Volume: 24,908
Technical Sentiment Signal: Sell
Current Market Cap: $8.56M
See more insights into APRE stock on TipRanks’ Stock Analysis page.